ReviewGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Update on pellucid marginal degeneration.
Review in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeTo review recent developments (2014-2024) in the diagnosis and treatment of pellucid marginal degeneration (PMD), focusing on advances in corneal imaging technologies, biomechanical assessments, and the effectiveness of current contact lens treatments and surgical techniques. Additionally, to discuss the role of PMD in cataract surgery and the use of toric intraocular lenses (IOLs).
methodStructured search of PubMed, Scopus, and Embase (Nov 2024; Jan 2014-present) using PMD-related keywords/MeSH. After dual independent screening of 129 citations using predefined inclusion/exclusion criteria, 50 articles met eligibility and were included.
resultsRecent technologies enable better assessment of corneal curvature and pachymetry relationships, aiding differentiation of PMD from other ectatic diseases. Advances in biomechanical assessments have improved early detection and diagnostic precision. Most patients can be managed conservatively with new types of rigid contact lenses. Modified corneal cross-linking (CXL) protocols show promise in stabilizing the disease. Lamellar transplants offer visual outcomes comparable to penetrating keratoplasty with fewer complications. Wedge resection shows promising outcomes, but larger studies with long-term follow-up are still required. In cataract surgery, toric IOLs may provide effective astigmatism correction in selected PMD patients.
conclusionThe diagnosis and treatment of PMD have significantly evolved in the last decade. Improved imaging and biomechanical assessments aid in accurate diagnosis. Contact lenses and lamellar surgery are mainstay treatments. Future clinical studies should focus on the CXL protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.